# US 2026/0098246 A1 · Compositions and processes for engineering ureteric bud kidney tissues and in-vitro compositions thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098246 A1
- Document ID: US20260098246A1
- Status: Published application
- Kind: A1
- Application number: 19/285,431
- Filed: 2025-07-30
- Published: 2026-04-09
- Earliest claimed: 2024-10-03
- Assignees: Trestle Biotherapeutics, Inc.
- Applicants: Trestle Biotherapeutics, Inc.
- Inventors: Benjamin Shepherd; Alice Chen; J. William Higgins, III
- Web page: https://patentgrep.com/patent/US20260098246A1

## CPC

- C12N 5/0686: {Kidney cells}
- B33Y 80/00: Products made by additive manufacturing
- C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)}
- C12N 5/0687: {Renal stem cells; Renal progenitors}
- C12N 2500/84: from mammals
- C12N 2501/113: Acidic fibroblast growth factor (aFGF, FGF-1)
- C12N 2501/119: Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- C12N 2501/13: Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/385: of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2513/00: 3D culture
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- B33Y: ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING

## Abstract

This disclosure provides compositions comprising engineered ureteric bud kidney tissues and methods of making lumenized ureteric bud kidney tissues. Also provided herein are in vitro kidneys comprising nephron progenitor cells and ureteric bud cells. Methods of making the compositions and in vitro kidneys and uses thereof are disclosed herein. In some aspects, provided herein are methods for generating a lumenized kidney tissue having a spatially-controlled 3-dimensional (3D) tubular architecture in vitro.

## Claims

### Claim 1

A method for generating a lumenized kidney tissue having a spatially-controlled 3-dimensional (3D) tubular architecture in vitro, the method comprising:
(a) generating a plurality of ureteric bud (UB) kidney tissues from a population of Wolffian duct progenitor cells that express CXCR4, cKit, or a combination thereof;
(b) spatially arranging the plurality of UB kidney tissues in a sequential configuration and in a proximity sufficient to form fused UB kidney tissues that are contiguously fused from at least one connecting point; and
(c) culturing the fused UB kidney tissues in a branching medium, thereby forming a lumenized kidney tissue having a spatially-controlled 3D tubular architecture,
wherein the lumenized kidney tissue upon contact with a fluid facilitates fluid flow through the spatially-controlled 3D tubular architecture.

### Claim 2 (depends on 1)

The method of claim 1, wherein the Wolffian duct progenitor cells are differentiated from human induced pluripotent stem cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein the Wolffian duct progenitor cells further express PAX2, EMX2, LHX1, RET1, HOXB7, or a combination thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the generating comprises aggregating the Wolffian duct progenitor cells using centrifugation and differentiating the aggregated Wolffian duct progenitor cells in a suspension culture.

### Claim 5 (depends on 1)

The method of claim 1, wherein the generating further comprises enriching the Wolffian duct progenitor cells for CXCR4 and cKit expressing Wolffian duct progenitor cells.

### Claim 6 (depends on 1)

The method of claim 1, wherein the generating comprises contacting the Wolffian duct progenitor cells with a cell culture medium comprising: retinoic acid, fibroblast growth factor 9 (FGF9), LDN193189, CHIR99021, fibroblast growth factor 1 (FGF1), glial-derived neurotrophic factor 1 (GDNF), Y27632, and a solubilized basement membrane preparation extracted from Engelbreth-Holm-Swarm (EHS) mouse sarcoma.

### Claim 7 (depends on 1)

The method of claim 1, wherein the arranging comprises bioprinting the plurality of UB kidney tissues.

### Claim 8 (depends on 1)

The method of claim 1, further comprising connecting the plurality of UB kidney tissues to a population of nephron progenitor cells (NPCs) to form a contiguous tubular network between the NPCs and the plurality of UB kidney tissues.

### Claim 9 (depends on 1)

The method of claim 1, wherein the branching medium comprises retinoic acid, RSPO1, a neurotrophic factor, a fibroblast growth factor, a bone morphogenetic pathway inhibitor, an extracellular matrix, or a combination thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein the at least one connecting point comprises:
(a) a tip of a UB kidney tissue of the plurality of UB kidney tissues;
(b) a stalk a UB kidney tissue of the plurality of UB kidney tissues;
(c) a tip of a UB kidney tissue and a stalk of a UB kidney tissue;
(d) one or more tips of an adjacent UB kidney tissue of the plurality of UB kidney tissues;
(e) one or more stalks of an adjacent UB kidney tissue of the plurality of UB kidney tissues;
(f) two or more tips of adjacent UB kidney tissues of the plurality of UB kidney tissues; or
(g) two or more stalks of adjacent UB kidney tissues of the plurality of UB kidney tissues;
(h) cells isolated from (a)-(c) or a combination thereof; or
(i) a combination of any one of (a)-(h).

### Claim 11

An in vitro composition comprising:
an in vitro-differentiated human kidney tissue comprising a population of human nephron progenitor cells (NPCs) connected to a population of fragmented ureteric bud (UB) kidney tissues,
wherein:
the in vitro-differentiated human kidney tissue comprises a collecting duct,
and the in vitro-differentiated human kidney tissue comprises two or more markers selected from: LRP2, GATA3, MAFB, EpCAM, PODXL and CK8.

### Claim 12

An in vitro-differentiated human kidney tissue comprising:
a population of human nephron progenitor cells (NPCs) connected to a population of fragmented ureteric bud (UB) kidney tissues differentiated from Wolffian duct progenitor cells,
wherein the in vitro-differentiated human kidney tissue comprises repeating units of nephric-ureteric connections in a sequential configuration.

### Claim 13 (depends on 12)

The in vitro-differentiated human kidney tissue of claim 12, wherein each unit of the nephric-ureteric connections is at least about 1 millimeter to about 10 millimeters in size.

### Claim 14 (depends on 12)

The in vitro-differentiated human kidney tissue of claim 12, further comprising a solubilized basement membrane preparation extracted from Engelbreth-Holm-Swarm (EHS) mouse sarcoma.

### Claim 15 (depends on 12)

The in vitro-differentiated human kidney tissue of claim 12, wherein the in vitro-differentiated kidney tissue comprises a lumenized collecting duct.

### Claim 16 (depends on 15)

The in vitro-differentiated human kidney tissue of claim 15, wherein the collecting duct expresses a marker selected from: GATA3, EPCAM, and ECAD.

### Claim 17 (depends on 12)

The in vitro-differentiated human kidney tissue of claim 12, wherein the in vitro-differentiated kidney tissue comprises a proximal tubule.

### Claim 18 (depends on 12)

The in vitro-differentiated human kidney tissue of claim 12, wherein the repeating units of nephric-ureteric connections express two or more markers selected from: CK8, MAFB, LRP2, EpCAM, PODXL, and GATA3.

### Claim 19 (depends on 12)

The in vitro-differentiated human kidney tissue of claim 12, wherein the repeating units of nephric-ureteric connections express a nephron marker, wherein the nephron marker comprises MAFB or LRP2.

### Claim 20 (depends on 12)

The in vitro-differentiated human kidney tissue of claim 12, wherein the repeating units of nephric-ureteric connections express a UB marker, wherein the UB marker is selected from the group consisting of RET1, SOX9, CK8, and GATA3.

### Claim 21 (depends on 12)

The in vitro-differentiated human kidney tissue of claim 12, wherein the in vitro-differentiated kidney tissue comprises a glomerular marker, a proximal tubule marker, a tubular epithelium marker, and a connecting segment marker.

### Claim 22 (depends on 21)

The in vitro-differentiated human kidney tissue of claim 21, wherein the glomerular marker comprises MAFB, WT1, nephrin, or podocin.

### Claim 23 (depends on 21)

The in vitro-differentiated human kidney tissue of claim 21, wherein the proximal tubule marker comprises LRP2, LTL, CUBN, PTH1R, AQP1, CLDN2, TJP3, or CD13.

### Claim 24 (depends on 21)

The in vitro-differentiated human kidney tissue of claim 21, wherein the tubular epithelium marker comprises CK8, AQP isoforms, CD34, WGA lectin.

### Claim 25 (depends on 21)

The in vitro-differentiated human kidney tissue of claim 21, wherein connecting segment marker comprises GATA3 or AQP2.

### Claim 26 (depends on 12)

The in vitro-differentiated human kidney tissue of claim 12, wherein the human NPCs are derived from human embryonic stem cells, human induced pluripotent stem cells (iPSCs), or human adult stem cells.

### Claim 27 (depends on 12)

The in vitro-differentiated human kidney tissue of claim 12, wherein a portion of a core of the UB kidney tissues comprise epithelial cells, renal stromal cells, or a combination thereof.

### Claim 28 (depends on 12)

The in vitro-differentiated human kidney tissue of claim 12, wherein the Wolffian duct progenitor cells express CXCR4 and cKit; and at least one marker selected from the group consisting of PAX2, EMX2, LHX1, RET1 and HOXB7.

### Claim 29

A method of generating a lumenized in vitro-differentiated human kidney tissue, the method comprising:
(a) differentiating a population of human induced pluripotent stem cells (iPSCs) to a population of Wolffian duct progenitor cells;
(b) isolating Wolffian duct progenitor cells expressing a marker selected from CXCR4, cKit, or a combination thereof;
(c) contacting the Wolffian duct progenitor cells isolated from (b) with a first cell culture medium and culturing the Wolffian duct progenitor cells for at least 48 hours in static cell culture conditions, wherein the first cell medium comprises: retinoic acid, fibroblast growth factor 9 (FGF9), LDN193189, CHIR99021, fibroblast growth factor 1 (FGF1), glial-derived neurotrophic factor 1 (GDNF), Y27632, a solubilized basement membrane preparation extracted from Engelbreth-Holm-Swarm (EHS) mouse sarcoma, or a combination thereof;
(d) arranging the Wolffian duct progenitor cells in a sequential configuration and in a proximity sufficient to form fused UB kidney tissues that are contiguously fused from at least one connecting point; and
(e) culturing the fused UB kidney tissues in a branching culture medium for at least 48 hours to form a lumenized in vitro-differentiated human kidney tissue, wherein the branching culture medium comprises retinoic acid, RSPO1, a neurotrophic factor, a fibroblast growth factor, a bone morphogenetic pathway inhibitor, an extracellular matrix, or a combination thereof.

### Claim 30 (depends on 29)

The method of claim 29, wherein the method further comprises combining the lumenized in vitro-differentiated human kidney tissue with a population of in vitro-differentiated human nephron progenitor cells (NPCs) and allowing the combination of the lumenized in vitro-differentiated human kidney tissue and the population of in vitro-differentiated human NPCs to form a contiguous tubular network.
